NXTC

Nextcure

• TipRanks·1d ago

  NextCure granted Fast Track Designation for SIM0505 by FDA

• Reuters·1d ago

  NextCure wins FDA Fast Track for SIM0505 in platinum-resistant ovarian cancer

• Benzinga·1d ago

  NextCure's SIM0505 Receives FDA Fast Track For Platinum-Resistant Ovarian Cancer, Phase 1 Data To Be Presented At ASCO 2026

• Reuters·1d ago

  NEXTCURE RECEIVES FAST TRACK DESIGNATION FOR SIM0505 (CDH6 ADC) IN OVARIAN CANCER

• Reuters·03/31 20:08

  NextCure, Simcere CDH6 ADC abstract accepted for ASCO meeting

• Benzinga·03/23 21:05

  12 Health Care Stocks Moving In Monday's After-Market Session

• Seeking Alpha·03/06 07:47

  NextCure GAAP EPS of -$19.65

• Reuters·03/05 21:18

  NextCure Publishes Corporate Presentation on Targeted ADC Cancer Therapies

• Reuters·03/05 21:17

  NextCure reports marginal increase in 2025 net loss

• Benzinga·03/05 21:14

  NextCure Q4 EPS $(0.81) Beats $(2.42) Estimate

• Dow Jones·03/05 21:12

  *NextCure 2025 Loss/Shr $19.65 >NXTC

• Dow Jones·03/05 21:11

  *NextCure Sees Funding Oper Expenses and Cap Expenditures Into 1H of 2027 Through Proof-Of-Concept for SIM0505 >NXTC

• Dow Jones·03/05 21:11

  *NextCure Expects Current Fincl Resources to Sufficient to Fund Oper Expenses and Cap Expenditures Into 1H of 2027

• Dow Jones·03/05 21:10

  *NextCure: LNCB74 Phase 1 Dose Escalation Trial Update Planned in 2H of 2026 >NXTC

• TipRanks·03/02 14:55

  NextCure trading resumes